Non-small Cell Lung Cancer Clinical Trial
Official title:
Phase II Study of Biweekly Schedule of Docetaxel and Cisplatin in High Risk Patients With Unresectable Non-small Cell Lung Cancer
The rationale of phase II study of biweekly docetaxel and cisplatin in patients with
unresectable NSCLC are follows:
First, the optimal dose and schedule of combination with docetaxel and cisplatin are still
controversial (3 weekly versus weekly).
Platinum-based combination chemotherapy improves the survival of patients with advanced
non-small cell lung cancer (NSCLC) in the first-line setting.
Combination chemotherapy with docetaxel and cisplatin is one of the standard platinum-based
regimens for treating NSCLC. However, usual standard 3 weekly regimen with docetaxel and
cisplatin have consistently produced frequent Grade 3-4 neutropenia, and febrile
neutropenia.
Although weekly docetaxel and cisplatin is better tolerated than chemotherapy every 3 weeks,
especially in the first line setting in terms of myelosuppression, the optimal dose and
schedule for administration of the two drugs has not yet been determined.
Both 3-weekly docetaxel plus cisplatin and weekly schedule showed similar response rates but
had different toxicity profiles. The most frequent grade 3 or 4 toxicities were neutropenia
in the 3 weekly schedule and fatigue or asthenia in the weekly schedule.
Second, docetaxel and cisplatin have different action and mechanism. Docetaxel showed
characteristic early bone marrow suppression 5-7 days after infusion compared with usual 14
days after infusion of cisplatin. Thus, nadir period is not overlapped when the
investigators administered both drugs concomittantly.
Third, there are many feasible reports of biweekly administration of docetaxel in patients
with NSCLC, breast cancer, stomach cancer, and ovarian cancer with better safety profiles.
Therefore,the investigators designed this phase II study to evaluate the efficacy and
toxicity of biweekly schedule of docetaxel and cisplatin in patients with unresectable NSCLC
and test the hypothesis that biweekly schedule of docetaxel and cisplatin is better
tolerated than both standard 3 week and weekly schedule in terms of hematologic
(neutropenia) and non-hematologic toxicities (asthenia, interstitial pneumonitis.
Additionally the investigators will evaluate polymorphism associated with this study.
Study design is followings: The sample size was calculated according to Simon's two stage
optimal design. Assuming a response rate of 40%, a probability of error of 5% and a power of
80%, a total of 48 patients (43 patients plus 5 patients to compensate a 10% drop-out rate)
were enrolled. In the initial stage, 13 evaluable patients were to be entered into the study
and evaluated for their response. If ≥ 3 responses were observed during the first stage,
then 30 additional patients were to be entered in the second stage. The statistical
evaluation was performed based on the intention to-treat analysis.
The combination chemotherapy consisted of docetaxel of 40mg/m2 as a 1-hour infusion followed
by cisplatin 40mg/m2 as a 30-minutes intravenous infusion and both drugs were given on days
1, and 15 in an outpatient setting. Patients also received adequate hydration with at least
1,500ml of half saline or normal saline before cisplatin administration. All the patients
received antiemetic therapy that consisted of intravenous 5-HT3 antagonist and dexamethasone
before docetaxel administration. The treatment cycles were repeated every 4 weeks until the
maximum six cycles.
The patients whose absolute neutrophil count and platelet count were greater than or equal
to 1.500 and 100,000/mm3, respectively, and who had lower than or equal to grade 1
non-hematologic toxicity (excluding alopecia) received chemotherapy on day 1 of each cycle.
On days 15 of each cycle, the minimum requirements to receive chemotherapy were an absolute
neutrophil count between 1000 and 1,500/mm3, a platelet count ≥75,000/mm3 and no grade ≥2
nonhematologic toxicity (excluding alopecia).
If these conditions were not met on days 1, or 15, then chemotherapy was postponed for 1
week. A delay of more than 3 weeks resulted in withdrawal from the study.
If there were any grade 3 to 4 hematologic toxicities at the nadir of the previous cycle, or
febrile neutropenia with or without documented infection, then administration of both drugs
in the subsequent cycles was reduced by 25% from the planned dose.
The Administration of granulocyte-colony stimulating factor (G-CSF) was allowed in the
presence of febrile neutropenia, and grade 3 or 4 neutropenia.
In the presence of grade 3 or 4 non-hematologic toxicity (except nausea, vomiting and
alopecia), the treatment was postponed until resolution of the toxicity and then both drug
doses were reduced by 25% for the next cycle. Treatment was stopped at any time for
documented disease progression, unacceptable toxicity or according to the patient's own
refusal.
The pretreatment baseline evaluation included a complete medical history and physical
examination, a complete blood cell count (CBC) with the differentials, chemistry profiles
and performance status. Chest X-rays, chest and upper abdominal computed tomography (CT)
scans, brain CT scan or magnetic resonance imaging, a radionuclide bone scan and other
diagnostic procedures were performed as clinically indicated.
During treatment, a limited history taking, physical examination, assessment of toxicity, a
complete blood cell count with the differentials and blood chemistry tests were repeated
weekly. A chest X-ray was performed every 4 weeks before each cycle.
Appropriate imaging studies, including CT scans of the chest and upper abdomen, were
performed every two cycles to assess the treatment response, and sooner if needed for
documenting disease progression. The objective tumor responses were assessed according to
the RECIST criteria. The response rate was calculated as the ratio of the number of patients
who achieved a complete or partial response to the number of enrolled patients. Overall
survival (OS) and Time to progression (TTP) were calculated from the start of therapy until
death and progression, respectively, or until the last follow-up. Toxicities were evaluated
according to the National Cancer Institute Common Toxicity Criteria (NCI-CTC) scale version
3.0.
;
Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT03087448 -
Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1 | |
Recruiting |
NCT05042375 -
A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT02526017 -
Study of Cabiralizumab in Combination With Nivolumab in Patients With Selected Advanced Cancers
|
Phase 1 | |
Enrolling by invitation |
NCT00068003 -
Harvesting Cells for Experimental Cancer Treatments
|
||
Terminated |
NCT05414123 -
A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide
|
||
Recruiting |
NCT05059444 -
ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
|
||
Recruiting |
NCT05919537 -
Study of an Anti-HER3 Antibody, HMBD-001, With or Without Chemotherapy in Patients With Solid Tumors Harboring an NRG1 Fusion or HER3 Mutation
|
Phase 1 | |
Recruiting |
NCT05009836 -
Clinical Study on Savolitinib + Osimertinib in Treatment of EGFRm+/MET+ Locally Advanced or Metastatic NSCLC
|
Phase 3 | |
Recruiting |
NCT03412877 -
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
|
Phase 2 | |
Active, not recruiting |
NCT03170960 -
Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03219970 -
Efficacy and Safety of Osimertinib for HK Chinese With Metastatic T790M Mutated NSCLC-real World Setting.
|
||
Recruiting |
NCT05949619 -
A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors
|
Phase 1/Phase 2 | |
Recruiting |
NCT04054531 -
Study of KN046 With Chemotherapy in First Line Advanced NSCLC
|
Phase 2 | |
Withdrawn |
NCT03519958 -
Epidermal Growth Factor Receptor (EGFR) T790M Mutation Testing Practices in Hong Kong
|
||
Completed |
NCT03384511 -
The Use of 18F-ALF-NOTA-PRGD2 PET/CT Scan to Predict the Efficacy and Adverse Events of Apatinib in Malignancies.
|
Phase 4 | |
Terminated |
NCT02580708 -
Phase 1/2 Study of the Safety and Efficacy of Rociletinib in Combination With Trametinib in Patients With mEGFR-positive Advanced or Metastatic Non-small Cell Lung Cancer
|
Phase 1/Phase 2 | |
Completed |
NCT01871805 -
A Study of Alectinib (CH5424802/RO5424802) in Participants With Anaplastic Lymphoma Kinase (ALK)-Rearranged Non-Small Cell Lung Cancer (NSCLC)
|
Phase 1/Phase 2 | |
Terminated |
NCT04042480 -
A Study of SGN-CD228A in Advanced Solid Tumors
|
Phase 1 | |
Recruiting |
NCT05919641 -
LIVELUNG - Impact of CGA in Patients Diagnosed With Localized NSCLC Treated With SBRT
|
||
Completed |
NCT03656705 -
CCCR-NK92 Cells Immunotherapy for Non-small Cell Lung Carcinoma
|
Phase 1 |